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Adrenocortical carcinoma is a rare and aggressive cancer and its prognosis is frequently unsatisfactory.
Due to its rarity there's a lack of prospective randomized studies. Without experience in the approach of
this kind of tumor, managing becomes challenging and, moreover, we have only few recommendations,
based on weak evidence. We report a case that has some peculiarities and is an excellent food for
thought. Then we deal with a literature review to highlight and summarize most signiﬁcant aspects of
epidemiology, clinic, diagnosis, therapy and prognosis in an exquisitely surgical point of view.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Primary carcinoma of the adrenal cortex (Adrenocortical Carci-
noma, ACC) is a rare and highly aggressive cancer with a frequently
dismal prognosis. It affects worldwide approximately 1e2 new
patients per million people a year [1e10], accounting for 0.2% of
cancer-related deaths in the United States [7,8]. Due to the high and
increasing incidence of benign adrenal lesions and incidentalomas,
differential diagnosis becomes essential but it's not ever clear
preoperatively [5,11]. With respect to the ability of hormone pro-
duction, ACCs can be functioning or non-functioning tumors
[12,13]. The rarity of the disease and its dismal prognosis require a
multidisciplinary approach to improve results [12]. Indeed diag-
nosis is often delayed, many patients present at advanced stages
and the tumor is quite unresponsive to chemotherapy [14e25].
Recurrences, both local and metastatic, are reported in up to 85% of
patients after resection [26,27], and overall the prognosis remains
poor, with a 5-year survival rate of 16%e47% [1,5,24,28]. Radical
surgical resection, avoiding tumor rupture, remains the mainstay of
therapy and the most important prognostic factor [14e29]. The
very low incidence of the disease has precluded several statistically
signiﬁcant studies that would be needed to improve the manage-
ment of patients with ACCs. In fact most of recommendations areesiato).
by Elsevier Ltd. All rights reservedderived from retrospective series or expert opinions, whereas only
few of them are based on prospective clinical trials [1e29]. In order
to emphasize several issues of differential diagnosis and treatment,
we describe the peculiar case of a 53-old-man with a gigantic ACC
that we operated with excellent results; in addition, we report the
results of our literature review to summarize all the existing
knowledge of surgical interest on this topic.2. Case report
A 53-year-old man was found to have a large mass in the left
upper abdomen. He was 177 cm tall and weighed 90 kg. He had
always been healthy but, during the last 3 months, he was com-
plaining dull, vague abdominal pain localized to the left quadrants.
He didn't report colicky pain, nor nausea, vomiting, fever, weight
loss. Vital signs were normal. Abdominal inspection highlighted a
large swelling amid left quadrants and the palpation revealed a
huge lump of around 20 cm  20 cm, that started from the left
hypochondrium and exceeded the transverse umbilical line. It was
smooth, ﬁrm-to-hard in consistency and was not moving with
respiration. Ultrasonography showed left kidney caudally and
medially displaced by a large, roundish, hypo-isoechoic solid mass
at the upper pole of the left kidney. The chest radiograph did not
reveal any abnormality. CT scan showed a gross solid mass with
inhomogeneous density, 21  18 cm, closely adjacent to the
pancreas' tail, inseparable from the psoas muscle. There were no.
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that it was a renal heteroplasia. Functioning of both kidneys was
normal on intravenous urography. We measured levels of adrenal
hormones (glucocorticoids, mineralocorticoids, sexual steroids and
steroid precursors, catecholamines, metanephrines) and all were
normal. Bone scintigraphy was performed to exclude skeletal me-
tastases and it was negative. A ﬁne needle biopsy was performed
and it just identiﬁedmalignant cells but didn't raise the suspicion of
adrenal origin's mass. The case was further discussed in a multi-
disciplinary team meeting comprising urologists, radiologists, and
oncologists: the diagnosis of renal heteroplasia was considered as
the most likely. The patient signed a consent for radical left ne-
phrectomy and underwent it. We performed a laparotomy, using a
largemedian anterior approach. Peroperatively the lesion appeared
as a single mass, strongly adherent to the upper pole of left kidney,
without any cleavage plan. Histopathology conﬁrmed the diagnosis
of non-functional ACC of 24  21  19 cm. It showed few mitosis
(2e3  30 HPF). Left kidney measured 14  10  8 cm and its pa-
renchyma was free from cancer. The patient's postoperative course
was complicated by acute renal failure but it was successfully
controlled by drugs. He was discharged on the 30th postoperative
day in good conditions. The medical oncologist, radiologist and
endocrinologist followed the patient for the next 60 months. No
adjuvant treatment was initiated. He has been regularly followed-
up and now, after 14 years, he's alive and well. The case described
is shown for his own peculiarities because, normally, the prognosis
is much more ominous, especially with so advanced cancers. This
underlines the importance of mitotic index and, more generally, the
aggressiveness of the tumor, which, in the case we described, were
certainly not very high.
3. Literature review
3.1. Materials and methods
A literature search, using the Medline/PubMed database for full-
length papers, was performed up to 31 January 2014. Entry terms
were: adrenal cancer, adrenocortical carcinoma, treatment, sur-
gery, laparoscopy, staging and prognosis. Out of the retrieved re-
cords, those pertinent to the objective of the present review were
selected. The corresponding full-length articles were examined
carefully and those articles with clinical relevance were considered
for analysis. Review articles and the most recent guidelines and
consensus reports on management of adrenal incidentalomas and
ACC by the European Network for the Study of Adrenal Tumours
(ENSAT), American Association of Clinical Endocrinologists and
American Association of Endocrine Surgeons, were also analyzed
and critically reviewed.
3.2. Epidemiology
ACC is a rare solid tumor [6,24]. The exact incidence is difﬁcult to
determine and most authors estimate an incidence of 1e2 per
million population [1,5,24,30]. In contrast, adrenal incidentalomas
have a prevalence of at least 3% in a population >50 yr of age (ACC
constitute <5% of all adrenal incidentalomas) [31e35]. However,
ACC prevalence depends on the size of the tumor, accounting for 2%
of lesions <4 cm, 6% of lesions 4e6 cm, and 25% of lesions >6 cm
[36]. ACC affects women more commonly than men with a ratio of
1.5:1 [1,25,37e41]. Females with ACC are more likely to have
functional tumors. Men with ACC tend to have functional tumors
before the age of 20 years and non-functional tumors after the age
of 40 years [3,13,14]. Some reports indicate a bimodal age distri-
bution, with a ﬁrst peak in childhood (<5 years) and a second
higher peak in the fourth and ﬁfth decades [3,11,13,24,39,40]. Inadults, the mean age of diagnosis is 45 years [24]. The incidence of
ACC is 10e15 times higher in children in southern Brazil, which is
related to an inherited germline p53 mutation [42,43]. Indeed,
while ACC most frequently arises sporadically and without known
pathogenesis, it has been also associated with a number of familial
tumor syndromes, includingmultiple endocrine neoplasia type 1 or
MEN-1 (mutation of the MEN1 tumor suppressor at 11q13), Li-
Fraumeni syndrome (p53 mutation on 17p13), Beck-
witheWiedemann syndrome (alterations of gene clusters on
11p15.5 and 15q11e13), and Carney complex (mutation of
PRKAR1A gene at 17q23e24 or mutations at 2p16) [44,45].
3.3. Clinical presentation
ACC can be asymptomatic or can present with symptoms of
hormone excess or complaints referable to the mass [3,11].
Generally ACC present an immature steroidogenesis and almost all
of these tumors exhibit hormonal precursor excess but, approxi-
mately, 60% of all ACC patients will present with hormone-related
signs and symptoms (so-called “functional tumors”) [3,11].
Around 60% of cases of functional tumors present with signs and
symptoms of Cushing's syndrome that most commonly is rapidly
progressing [39,45,46]. Indeed rapid course of illness is highly
suspicious of ACC or should suggest ectopic ACTH secretion by a
malignant neoplasm. Classic signs of Cushing's syndrome are
truncal obesity, facial plethora, rounded “moon” facies, thinning of
skin, easy bruising, muscle weakness, supraclavicular fat pads,
menstrual irregularity, hypertension, glucose intolerance up to
frank diabetes mellitus, osteoporosis with fractures, renal calculi
and psychiatric disturbances. Androgen-secreting ACCs in women
may present with virilization and associated hirsutism, deepening
of the voice, breast atrophy, male pattern baldness, acne, andro-
genetic efﬂuvium, clitoral hypertrophy, oligomenorrhea, and
altered libido. These androgen-related signs and symptoms can,
sometimes, coexist with Cushing's syndrome while, most
commonly, they don't. Also in this case, the rapid development of
the symptoms should suggest ACC-related androgen excess, instead
of more common reasons, like polycystic ovary syndrome.
Estrogen-secreting adrenal tumors are less frequent (5e10% ofmale
patients), but if present are almost pathognomonic for ACC. These
tumors may result in feminization with gynecomastia, breast
tenderness, decreased libido, and testicular atrophy. Symptoms of
isolated mineralocorticoid (aldosterone) excess with severe hy-
pertension and hypokalemia are rare (2e5% of all functional tu-
mors) [47,48]. Patients with a non-functional ACC usually present
with symptoms related to local mass: abdominal discomfort,
nausea, vomiting, abdominal fullness, indigestion, back pain. In
these cases, the tumors are mostly larger than 10 cm in diameter.
Non-speciﬁc symptoms such as fever, weight loss, and loss of
appetite are less typical in patients with ACC.
3.4. Diagnosis
The initial evaluation of all patients with adrenal tumors >1 cm
should determine whether the tumor is functional or not and
should deﬁne the extent of disease [49,50]. In 2006 standards for
diagnostic procedures in patients with suspected or established
ACC have been proposed by the ACCworking group of the European
Network for the Study of Adrenal Tumors (ENSAT) and endorsed by
colleagues outside of Europe [51]. Theymay be useful to outline the
diagnostic iter although the evidence level is low. Endocrine
assessment prior to surgery is mandatory, for all patients with
suspected ACC, as it is for all adrenal tumors and the pattern of
secretion is useful for more than simply establishing the adreno-
cortical origin of the tumor [49,50]. Endocrine assessment is
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moreover, hormones may serve as tumor markers during follow-
up. Furthermore we must consider that an excess of cortisol, if
undiagnosed, may lead to adrenal insufﬁciency after surgery.
Finally the steroid pattern is very important because, in general, co-
secretion of different steroids may be highly suspicious for ACC
[28,45]. Table 1 shows recommendation of the ACC working group
of the European Network for the Study of Adrenal Tumors (ENSAT)
for the hormonal workup of patients with suspected or proven
adrenocortical carcinoma. Following these hormonal investigations
only a minority of ACCs are hormonally inactive. Using gas chro-
matography/mass spectroscopy (GC/MS) for sophisticated urinary
steroid analysis, hormonal activity can be demonstrated in almost
all cases (more than 95%) of ACC [52]. However, due to low efﬁ-
ciency of intratumoral steroidogenesis or the exclusive secretion of
steroid precursors, tumors may appear clinically as hormonally
inactive. Careful search for abnormal adrenal steroid secretion re-
veals increased hormone production in up to 80% ACCs, even in
tumors that may appear clinically as non-functional [45,46]. In
these cases it is important to search for the precursor steroid and
avoid to inappropriately classify a tumor as non-functional or,
worst, tomisdiagnose a tumor of the adrenal region as an ACC. In all
patients with adrenal tumors, a pheochromocytoma has to be
excluded prior to surgery or any other invasive procedure by
determination of metanephrines in plasma or urine. Nowadays,
because of more frequent and improved abdominal imaging, an
increasing percentage of ACC is discovered incidentally
[35,48,53,54]. Size and appearance on radiologic imaging studies
are fundamental to distinguish benign and malignant lesions. For
differential diagnosis of an adrenal mass, computerized tomogra-
phy (CT) and magnetic resonance imaging (MRI) are currently
equally effective [55e57]. Surely size is the strongest predictor of
malignancy. Only 2% of tumors <4 cm are found to be ACC, while 6%
of tumors 4 < 6 cm, and 25% of tumors >6 cm [34,58]. In fact, ac-
cording to the NIH consensus of 2002, patients with tumors >6 cm
should be treated surgically [36]. Identiﬁcation of smaller ACCs can
be challenging and, when a small lump is found, imaging follow-up
is mandatory to detect early modiﬁcations. Various radiologic
techniques are employed, in addition to size, to discriminate be-
tween benign and malignant lesions, as unenhanced density
characteristics (Hounsﬁeld units, HU) [59] or intravenous contrast
wash-out characteristics [60e62]. Each radiologist, according to his
own experience, could use the methods he considers most appro-
priate. CT and MRI are also fundamental for determining resect-
ability and relationships to adjacent structures. Probably MRI is the
best method to determine invasion into adjacent organs and intoTable 1
Recommended diagnostic work-up for ACC.
Hormonal work-up in patients with suspected or proven adrenocortical carcinoma (A
Network for the study of adrenal tumors (ENSAT)
Glucocorticoid excess
(minimum three of four tests)
- Dexamethasone su
- Excretion of free u
- Basal cortisol (seru
- Basal ACTH (plasm





Mineralocorticoid excess - Potassium (serum)
- Aldosterone/renin
Exclusion of a phaeochromocytoma
(minimum one of three tests)
- Catecholamine exc
- Metanephrine excr
- Meta- and normeta
ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiandrosterone sulfate.the inferior vena cava. 18F-2-ﬂuoro-2-deoxy-D-glucose positron
emission tomography (FDG-PET), especially when used in combi-
nation with CT, may be useful in patients with suspected ACC
[63e65] but it raises several issues of differential diagnosis with
adenomas or phaeochromocytomas [57,64]. There is no agreement
on the appropriateness of ﬁne needle biopsy. Some authors argue
that, given the risk of needle-track metastasis [55,56], a biopsy
should be performed only in case of inoperability to target the
medical therapy or in patients with a history of cancer, a suspect
adrenal metastasis and no other signs of metastatic disease. Accu-
racy in distinction of adenomas versus metastasis is quite high
(90%) but it's not the same in distinguishing between adenoma
versus carcinoma of adrenal gland [67]. Furthermore, due to the
high false negative rate, a benign cytologic diagnosis does not rule
out malignancy. However, a biopsy without prior exclusion of a
phaeochromocytoma constitutes malpractice [68,69]. It should be
noted that on the patient of our case-report we performed a biopsy
becausewe suspected, preoperatively, that the lumpwas belonging
to the kidney.
3.5. Staging
TNM is the classic method of staging tumors and it is used as
well in the case of ACC. Staging prior to surgery is indispensable for
excluding distant metastases. About 30% of patients have metas-
tasis at the onset and lung and liver are the most frequent sites.
Radical surgical resection, when can be achieved, remains the
mainstay of therapy and the most important prognostic factor
[14e29] therefore it is mandatory to know preoperatively whether
distant metastasis are present or not. To achieve a good staging
several systems have been proposed. In 2004, the Union Inter-
nationale Contre Cancer (UICC) and the World Health Organization
(WHO) published a staging system [70] but it had some prognostic
limitations, especially between stages III and IV. Thus ENSAT, in
2008, proposed a revised TNM classiﬁcation [71] that was
conﬁrmed, in 2010, in an independent cohort from the United
States [72]. The ENSAT staging system is superior to other proposed
staging systems in predicting clinical outcome of patients with ACC.
In this staging system, stage III is deﬁned by tumor inﬁltration in
surrounding tissue or tumor thrombus in vena cava/renal vein or
positive lymph nodes, whereas stage IV is deﬁned only by the
presence of distant metastasis. Table 2 shows differences between
these staging systems. Preoperatively, CT of the chest and abdomen
is mandatory to ﬁnd out distant metastases. MRI could be used but
cannot substitute for a chest CT for small lung lesions. FDG-PETmay
detect distantmetastases not apparent on CTorMRI [73,74]. If thereCC) recommendations of the ACC working group of the European
ppression test (1 mg, 23:00 h)
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Staging systems' comparison for ACC.
UICC/WHO 2004 STAGE ENSAT 2008
T1, N0, M0 I T1, N0, M0
T2, N0, M0 II T2, N0, M0
T1-2, N1, M0 III T1-2, N1, M0
T3, N0, M0 T3-4, N0-1, M0
T3, N1, M0 IV Any M1
T4, N0-1, M0
Any M1
UICC ¼ Union Internationale contre le cancer.
WHO ¼World Health Organisation.
ENSAT ¼ European Network for the Study of Adrenal Tumours.
T1 ¼ tumor 5 cm; T2 ¼ tumor >5 cm; T3 ¼ tumor inﬁltration in surrounding
tissue; T4 ¼ tumor invasion in adjacent organs (ENSAT ¼ also venous tumor
thrombus in vena cava or renal vein); N0 ¼ no positive lymph nodes; M0 ¼ no
distant metastases; N1 ¼ positive lymph nodes; M1 ¼ presence of distant
metastasis.
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settle the question, while, in suspected brain lesions cerebral im-
aging is required.
3.6. Therapy
In patients with localized adrenal tumor, suspicious for ACC,
surgical resection should be considered. Suspicious features to
consider are: tumors size >4 cm, functional tumor, radiologic sus-
picious characteristics (see above). Local invasion and lymph node
involvement are very evocative. Complete resection is the only
curative option for localized ACC and should be pursued aggres-
sively by a qualiﬁed oncologic surgeon [75]. A margin-free com-
plete resection (R0 resection), as well as leaving the adrenal capsule
intact during resection, are crucial for achieving long-term cure
[1,49]. Routine removal of the adjacent kidney is not necessary,
thus, for tumors not invading the kidney, the surgeon should
perform a kidney-sparing adrenalectomy [76]. For tumors invading
surrounding tissue or organs, concomitant resection of kidney,
liver, spleen, pancreas, stomach, colon and wall of the vena cava
should be considered [66] even if, in primary ACCs, it is quite
infrequent that the tumor invades the liver or adjacent kidney.
Obviously this is not always predictable during surgery, as in our
case in which the tumor was strongly adherent to the kidney, such
as to look like a single mass, although histological examination has
then denied the spread to the renal parenchyma. For large, right-
sided lesions, the inferior vena cava (IVC) is often involved with
tumor. The presence of a tumor-thrombus in the inferior vena cava
or the renal vein is compatible with complete tumor resection
[5,77]. If tumor extraction is not feasible, the infrarenal IVC can
generally be resected without replacement. Managing of a tumor
involving the suprahepatic IVC, right atrium, or superior vena cava
(SVC) could be very challenging. Although is known that ACCs often
spread via lymphatic drainage, the importance of regional lymph
nodes resection has always been underestimated. A recent study
suggests that locoregional lymphadenectomy reduces risk for tu-
mor recurrence [79]. Open surgery is still the standard for all pa-
tients with resectable ACC and it is the required procedure for
tumors >10 cm and for all invasive tumors [78]. We recommend a
wide anterior approach which allows access to sites of potential
invasion and metastatic spread and to regional lymph nodes. Some
argue that postoperative steroid administration is necessary since it
is difﬁcult to predict whether the contralateral adrenal gland will
be able to compensate for. In fact it's an old concept that adrenal
insufﬁciency is a major cause of postoperative morbidity and
mortality [99]. Over the last two decades, laparoscopy has emerged
as the preferred approach to the adrenal. The role of laparoscopicadrenalectomy (LA) in suspected cases of adrenal malignancies is a
matter of debate. There were, in the past, some disastrous experi-
ences [80,81] in terms of oncologic results but several contempo-
rary reports now suggest that laparoscopy can be performed with
oncologic outcomes equivalent to open surgery [82e84]. We think
that laparoscopy is a feasible option for tumors <10 cm andwithout
evidence of invasive disease but only when performed by a trained
laparoscopic surgeon with experience in ACC [85e87]. In cases of
metastatic disease, surgery is still the ﬁrst-choice treatment, when
complete resection of the primary tumor and all metastases is
feasible and particularly in patients with endocrinopathy in which
debulking can alleviate symptoms. At times, limited hepatic re-
sections, omental and peritoneal debulking, and pulmonary met-
astasectomy should be considered. For larger tumors or when one
plans a pulmonary metastasectomy, a thoracoabdominal approach
may be necessary. Liver metastases can be treated with partial
hepatectomies. An alternative to surgery of liver metastases <5 cm
is radiofrequency ablation [88]. Reoperations are feasible for local
recurrence or single metastases but we think that it should be
considered if sufﬁcient time (at least 6 month) have elapsed since
the intervention and if the new lesions seem to be completely
excised [89,90]. Some authors argue that repeated radical re-
sections seem to improve survival [89,90] but the extent of beneﬁt
is difﬁcult to determine due to lack of randomized trials [22,91e93].
Adjuvant therapy is recommended for most patients because of
high recurrence rates, even after radical resection [26,27]. In a large
recent retrospective study, adjuvant mitotane prolonged disease-
free survival (DFS) and overall survival (OS) in comparison to two
independent control groups [94]. Radiation therapy has shown his
usefulness in several scenarios, i.e. to control local recurrence risk
(especially in R1-R2 resections) or, with palliative intent, in the
treatment of unresectable lesions or to control local symptoms
[38,95e97]. The role of cytotoxic chemotherapy is continuously
under investigation. The recommended ﬁrst-line cytotoxic treat-
ment regimens are etoposide, doxorubicin, cisplatin plus mitotane
[98], or streptozotocin plus mitotane [92]. In most patients mito-
tane abolish steroid secretion but, since uncontrolled hormone
secretionmight worsen signiﬁcantly quality of life andmay even be
life threatening, sometimes additional measures are required to
control endocrine symptoms, such as adrenostatic drugs (metyr-
apone, etomidate). About follow-up, it's repeated every 3 months
for the ﬁrst two years, including abdominal CT or MRI and hor-
monal markers, and kept on for at least 10 yr.
3.7. Prognosis
Tumor stage is still one of the best available prognostic factors
with a 5-year survival of 84% for stage I, 63% for stage II, 51% for
stage III and 15% for stage IV [28]. Overall 5-year survival, after
complete resection, in different series has ranged between 16% and
47%, while the median survival is less than one year in case of
incomplete resection [6,38,71,82,103]. Large tumor size (diameter
>12 cm) has been associated with inferior survival even after
complete resection [27]. In addition, the mitotic rate and other
histologic and immunohistologic parameters (i.e. tumor necroses,
atypical mitotic ﬁgures, Ki67 index, mutated TP53, etc.) have high
prognostic value [27,100e102]. As we have already said, patient we
have described had a very lowmitotic rate, despite huge dimension
and, in our opinion, this was a crucial aspect of his extraordinarily
good prognosis.
4. Conclusions
Adrenocortical carcinoma is a rare and difﬁcult to cure cancer.
Despite the studies, many of which are still ongoing, and
G. Benassai et al. / International Journal of Surgery 12 (2014) S22eS28S26continuous efforts, unfortunately, the prognosis remains unac-
ceptably poor. In order to approach the treatment of this cancer a
multidisciplinary team is required. However, current knowledge
leads to believe that we can achieve more and more encouraging
results. New prospective trials investigating the role of laparoscopic
surgery and the value of lymphadenectomy are mandatory. As
emphasized in this review, to get the best results, a sound knowl-
edge and a previous experience of this disease are needed and
patients should always be sent in high-volume referral centers.
Scientiﬁc collaboration between these centers will lead to future
improvements.
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